We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Valeant Faces More Questions From Congress, Investors
Valeant Faces More Questions From Congress, Investors
Valeant Pharmaceuticals faced renewed scrutiny Wednesday on two fronts, with a lawmaker accusing the company of obstructing a congressional investigation and investors questioning the company’s long-term viability in the face of a dismal earnings report.